Acadia Healthcare Company, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on November 5, 2025, reports on events occurring on October 30, 2025, and the third quarter ended September 30, 2025. The filing primarily addresses executive leadership changes and references the release of Q3 2025 operating and financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Executive Departure
On October 30, 2025, Dr. Nasser Khan notified the Company of his resignation as Chief Operating Officer (COO), effective November 3, 2025. The Company has initiated a search for a new COO, with interim duties assumed by other executive leadership members.
Compensation and Transition Arrangements
- Role Transition: Dr. Khan will serve as an executive advisor to the CEO through December 31, 2025.
- Separation Payment: A lump-sum payment of $515,000 is scheduled for no later than March 15, 2026.
- Performance Bonus: Dr. Khan remains eligible for a 2025 cash bonus based on actual performance, subject to Board or Compensation Committee discretion.
Outlook and Risks
The filing does not contain specific guidance, outlook commentary, or risk factors beyond the operational impact of the COO departure. The Company indicates that leadership duties are being managed internally during the transition.
Investor Verification Checklist
- Review the Q3 2025 press release (Exhibit 99) for specific revenue, earnings, and cash flow figures.
- Examine the full Transition and Separation Agreement (Exhibit 10) for detailed terms regarding Dr. Khan's advisory role and bonus criteria.
- Monitor future announcements regarding the appointment of a permanent Chief Operating Officer.